Back

Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat

26 August 2018 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: Targeting reverse remodelling in heart failure Treatment, Other ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Hon-Kan Yip

Chang Gung Memorial Hospital Kaohsiung, Kaohsiung (Taiwan)

6 More presentations in this session

Presentation thumbnail
Feasibility and efficacy of early donepezil with or without metoprolol in reperfused myocardial infarction rats
Doctor M. Li (Osaka, JP)
Abstract Slides
Presentation thumbnail
The best of two worlds: Vascular protection and decongestion without RAAS stimulation mediated by a novel dual acting V1a/V2 vasopressin receptor antagonist
Doctor P. Kolkhof (Wuppertal, DE)
Abstract Slides
Presentation thumbnail
Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53 , for the prevention of post-myocardial infarction heart failure
Mr Y. Chen (Rochester, US)
Abstract Slides
Presentation thumbnail
Empagliflozin improves left ventricular diastolic function in db/db mice without altering cardiac expression of enzymes relevant for ketone body or branched chain amino acid catabolism.
Miss J. Moellmann (Aachen, DE)
Abstract
Presentation thumbnail
Empagliflozin prevention of heart failure development in diabetes is associated with an improvement in cardiac energy producition
Professor S. Verma (Toronto, CA)
Abstract Slides

Access the full session

Session thumbnail
Targeting reverse remodelling in heart failure

The Event

Event poster

ESC Congress 2018

26 August 2018 10:05 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources